Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor

Executive Summary

Development of a single-isomer version of Knoll's Meridia anti-obesity therapy has uncovered five other potential indications for the "improved chemical entity," including stress incontinence, depression, attention deficit hyperactivity disorder, anxiety and chronic pain, Sepracor CEO Tim Barberich told the H&Q conference Jan. 12. The company hopes to complete a proof of concept study for the stress incontinence indication during 1999, Barberich said. Sepracor is also "gearing up" for a Phase III trial of (S)-oxybutinin for the treatment of urinary incontinence, and hopes to be able to launch the product by 2002
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel